Clinical trials
Transthyretin Amyloidosis clinical trials
Below are recruiting transthyretin amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06465810Recruiting
Observational study for ATTR amyloidosis patients
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
La Jolla, CaliforniaAges 18–130 - NCT07766135Recruiting
Liver and blood clotting in heart amyloidosis
This study looks at how the liver and blood clotting are affected in people with a type of heart disease called transthyretin amyloidosis. It may help doctors better understand and manage this condition.
Messina, SicilyAges 18 years+ - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT04561518Recruiting
Study of people with TTR amyloidosis worldwide
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
La Jolla, CaliforniaAges Any age - NCT07213297Recruiting
Program for hereditary transthyretin amyloidosis
This trial is for people with a specific inherited form of amyloidosis caused by a change in the TTR gene. It offers a comprehensive care program to help manage this rare condition.
Canuelas, Buenos AiresAges 18 years+ - NCT07695701RecruitingPhase 4
Heart imaging study for a new ATTR-CM treatment
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
St Louis, MissouriAges 18–80 - NCT05929209Recruiting
Studying blood markers in inherited heart-and-nerve amyloidosis
This study looks for “biomarkers” (measurable signs in blood or other tests) to understand inherited transthyretin amyloidosis, including in people who have not yet developed symptoms. Results may help researchers track the condition earlier and better understand how it changes over time.
Roma, IDAges 18 years+ - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
La Jolla, CaliforniaAges 18–85 - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80 - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Phoenix, ArizonaAges 18 years+ - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT06907186Recruiting
Psychological support program for amyloidosis patients and families
This study tests a structured psychological support program for people with hereditary transthyretin amyloidosis (ATTRv) with heart involvement, their caregivers, and those who carry the gene but have no symptoms yet. The goal is to see if the program is practical and well-accepted.
PaviaAges 18 years+ - NCT05758493RecruitingPhase 2
Iodine-124 scan study for systemic amyloidosis
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
Portland, OregonAges 40–90 - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT07314268Recruiting
Study of tiny blood particles in heart amyloidosis
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
São Paulo, São PauloAges 18 years+ - NCT07223203RecruitingPhase 3
Study of nucresiran for hereditary nerve condition (hATTR-PN)
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
Aurora, ColoradoAges 18–85 - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Tucson, ArizonaAges 18–90 - NCT07238426Enrolling by invitation
Heart screening for older adults in Ordu, Turkey
This study is a screening program in Ordu, Turkey, to find older adults (65+) who might have a heart condition called cardiac amyloidosis. It uses medical records and heart ultrasounds to check people who already have certain heart problems.
Ordu, OrduAges 65 years+ - NCT07644325Recruiting
Comparing Two Biopsy Methods for Carpal Tunnel Amyloidosis
This study compares two small tissue samples taken during carpal tunnel surgery to see which method best detects a protein disease (transthyretin amyloidosis) that can affect nerves and the heart. If you have carpal tunnel syndrome and are having surgery, this research may help doctors diagnose related heart or nerve problems earlier.
MontpellierAges 18 years+ - NCT04535349Recruiting
Imaging heart uptake of bone tracer in ATTR amyloidosis
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
CaenAges 18–100 - NCT06978660Recruiting
AI-powered ECG test for early cardiac amyloidosis
This trial tests if an AI can spot early signs of cardiac amyloidosis from a standard 10-second ECG. If successful, it could lead to faster diagnosis and treatment.
Evanston, IllinoisAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07298044RecruitingPhase 4
Switching from tafamidis to acoramidis for heart condition
This study checks how levels of a protein called transthyretin change in your blood when you switch from tafamidis to acoramidis. It is for people with a specific type of heart disease caused by abnormal protein buildup.
Sankt Pölten, Lower AustriaAges 18–90
Hear when a new Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Transthyretin Amyloidosis trials by city
Studies with a site in or near these metro areas.
Transthyretin Amyloidosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for transthyretin amyloidosis?
- Yes. Clin2 currently lists 45 recruiting transthyretin amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transthyretin amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transthyretin amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.